7 genomic sequencing mandates transforming clinical oncology in 2026
As we navigate through 2026, the global healthcare sector is witnessing a mandatory transition toward comprehensive genomic profiling for all stage-three cancer diagnoses. This regulatory shift, spearheaded by the European Medicines Agency and the US FDA, aims to eliminate the "trial-and-error" approach in chemotherapy. By...